TABLE 3.
Multivariable predictors of NT-proBNP trajectory class three after TAVR.
| Variables | Univariable | Multivariable-adjusted | ||
| OR (95% CI) | P-value | OR (95% CI) | P-value | |
| Baseline characteristics | ||||
| Age (y) | 1.021 (0.973–1.074) | 0.4081 | ||
| Male | 1.131 (0.571–2.306) | 0.727 | ||
| BMI (kg/m2) | 0.908 (0.818–1.003) | 0.0626 | ||
| STS (%) | 1.08 (1.045–1.119) | <0.0001 | ||
| NYHA ≥ Class III | 2.872 (1.415–5.713) | 0.0028 | 2.643 (1.069–6.508) | 0.0332 |
| Dyslipidemia | 0.762 (0.256–1.836) | 0.58 | ||
| Hypertension | 0.813 (0.41–1.608) | 0.5498 | ||
| Diabetes | 0.486 (0.143–1.251) | 0.1808 | ||
| Prior MI | 8.848 (1.873–32.247) | 0.0019 | ||
| Prior PCI | 3.705 (1.691–7.669) | 0.0006 | 6.179 (2.263–17.007) | 0.0003 |
| Prior stroke | 1.299 (0.205–4.53) | 0.7266 | ||
| PVD | 1.942 (0.805–4.21) | 0.111 | ||
| Atrial fibrillation | 1.056 (0.389–2.43) | 0.9055 | ||
| COPD | 0.577 (0.194–1.387) | 0.2625 | ||
| NT-proBNP (per 1,000 pg/ml increase) | 1.146 (1.114–1.183) | <0.0001 | 1.111 (1.072–1.155) | <0.0001 |
| eGFR (ml/min) | 0.931 (0.91–0.951) | <0.0001 | 0.964 (0.937–0.989) | 0.0084 |
| LVEF (%) | 0.944 (0.925–0.963) | <0.0001 | ||
| V max (m/s) | 0.647 (0.487–0.881) | 0.0035 | ||
| MPG (mm Hg) | 0.975 (0.956–0.993) | 0.0079 | ||
| AVA (m2) | 0.591 (0.139–2.248) | 0.4618 | ||
| BAV | 0.347 (0.152–0.724) | 0.0072 | ||
| Procedural complications | ||||
| New or aggravated AV block | 1.568 (0.681–3.302) | 0.2586 | ||
| Vascular complications | 0.438 (0.024–2.101) | 0.4209 | ||
| Annular rupture | NA | 0.9896 | ||
| Coronary obstruction | NA | 0.9881 | ||
| Circulation collapse | 5.614 (1.786–14.83) | 0.0011 | ||
| AR paravalvular ≥ moderate | 1.504 (0.08–8.356) | 0.7028 | ||
| AR transvalvular ≥ moderate | 5.434 (0.274–37.975) | 0.1347 | ||
| Postoperative medications | ||||
| Aspirin | 0.632 (0.32–1.264) | 0.1868 | ||
| ADP receptor inhibitor | 0.608 (0.306–1.242) | 0.1597 | ||
| Warfarin | 0.442 (0.071–1.488) | 0.2677 | ||
| Beta blocker | 2.598 (0.855–6.483) | 0.0594 | ||
| NOAC | NA | 0.9878 | ||
| AECI/ARB | 1.67 (0.694–3.608) | 0.2169 | ||
| Diuretics | 1.326 (0.523–2.945) | 0.5151 | ||
| Adverse events within 30-day post-TAVR | ||||
| MI | NA | 0.9896 | ||
| Stroke | NA | 0.9863 | ||
| Disabling stroke | NA | 0.9881 | ||
| Bleeding | NA | 0.9891 | ||
| Life threatening bleeding | NA | 0.9903 | ||
| New permanent pacemaker | NA | 0.9887 | ||
| New atrial fibrillation | NA | 0.9858 | ||
| Renal dysfunction | 22.412 (0.874–574.891) | 0.0291 | ||
AECI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; AVA, aortic valve area; BAV, bicuspid aortic valve; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MPG, mean pressure gradient; NOAC, non-vitamin K antagonist oral anticoagulants; NYHA, New York Heart Association; OR, odd ratio; PCI, percutaneous coronary intervention; PVD, peripheral vascular diseases; STS, Society of Thoracic Surgeons; V max, peak aortic velocity.